Orient EuroPharma Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orient EuroPharma Co., Ltd.
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2016.
Becton Dickinson President, Chairman and CEO Vincent Forlenza speaks to IN VIVO about the business prospects at Becton Dickinson as it integrates its major acquisition, CareFusion, and oversees a major internal group restructuring, and about his role as the current chairman of AdvaMed.
UCB has chosen Daiichi Sankyo as its new commercial partner in Japan for an epilepsy drug, building on an existing relationship in the allergy area.
- Drug Delivery
- Generic Drugs
- OTC, Consumer
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Cyntec Co. Ltd.
- OrientPHARMA Co., Ltd. (OP)